Review on experimental treatment strategies against Trypanosoma cruzi.

Simple item page
dc.contributor.authorMazzeti, Ana Lia
dc.contributor.authorOliveira, Patricia Capelari de
dc.contributor.authorBahia, Maria Terezinha
dc.contributor.authorMosqueira, Vanessa Carla Furtado
dc.date.accessioned2021-12-07T21:25:16Z
dc.date.available2021-12-07T21:25:16Z
dc.date.issued2021pt_BR
dc.description.abstractChagas disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi. Currently, only nitroheterocyclic nifurtimox (NFX) and benznidazole (BNZ) are available for the treatment of Chagas disease, with limitations such as variable efficacy, long treatment regimens and toxicity. Different strategies have been used to dis cover new active molecules for the treatment of Chagas disease. Target-based and phenotypic screening led to thousands of compounds with anti-T. cruzi activity, notably the nitroheter ocyclic compounds, fexinidazole and its metabolites. In addition, drug repurposing, drug combinations, re-dosing regimens and the development of new formulations have been evaluated. The CYP51 antifungal azoles, as posaconazole, ravuconazole and its prodrug fosravuconazole presented promising results in experimental Chagas disease. Drug combina tions of nitroheterocyclic and azoles were able to induce cure in murine infection. New treatment schemes using BNZ showed efficacy in the experimental chronic stage, including against dormant forms of T. cruzi. And finally, sesquiterpene lactone formulated in nanocar riers displayed outstanding efficacy against different strains of T. cruzi, susceptible or resistant to BNZ, the reference drug. These pre-clinical results are encouraging and provide interesting evidence to improve the treatment of patients with Chagas disease.pt_BR
dc.identifier.citationMAZZETI, A. L. et al. Review on experimental treatment strategies against Trypanosoma cruzi. Journal of Experimental Pharmacology, v. 13, p. 409-432, 2021. Disponível em: <https://www.dovepress.com/review-on-experimental-treatment-strategies-against-trypanosoma-cruzi-peer-reviewed-fulltext-article-JEP>. Acesso em: 10 jun. 2021.pt_BR
dc.identifier.doihttps://doi.org/10.2147/JEP.S267378pt_BR
dc.identifier.issn1179-1454
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/14119
dc.language.isoen_USpt_BR
dc.rightsabertopt_BR
dc.rights.licenseThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Fonte: o PDF do artigo.pt_BR
dc.subjectDrug discoverypt_BR
dc.subjectNew chemical entitiespt_BR
dc.subjectRepurposingpt_BR
dc.subjectDrug combinationpt_BR
dc.subjectNanomedicinept_BR
dc.titleReview on experimental treatment strategies against Trypanosoma cruzi.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_ReviewExperimentalTreatment.pdf
Size:
5.39 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEFAR - Artigos publicados em periódicos